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Summary
Background:  Over  30%  of  the  US  population  is  colonized  with  methicillin  resistant
Staphylococcus  aureus  (MRSA).  People  within  the  community,  without  factors  asso-
ciated  with  Hospital  Acquired  (HA)  MRSA,  present  with  skin  and  soft  tissue  infections
(SSTIs).  Community  Acquired  MRSA  (CA-MRSA)  is  resistant  to  antibiotics  typically  pre-
scribed  for  SSTI.  Many  SSTIs  are  treated  with  antibiotics  that  are  ineffective  against
drug  resistant  strains.
Study  objectives:  This  study  examines  the  incidence  of  SSTIs  associated  with  CA-
MRSA,  to  determine  if  an  increase  in  SSTI’s  is  associated  with  changes  in  prescribing
patterns  for  MRSA.
Methods:  A  secondary  analysis  of  the  National  Ambulatory  Medical  Care  Survey
(NAMCS)  and  National  Hospital  Ambulatory  Medical  Care  Survey  (NHAMCS)  data
was  used  to  detect  incidence  of  SSTIs  based  on  ICD-9  coding  between  the  periods
of  1997—2002  and  2003—2008.  Antibiotic  prescribing  patterns  were  examined  for
treatment.
Results:  Incidence  of  SSTIs  increased  by  84.7%  from  1997—2002  to  2003—2008.  Antibi-
otics  prescribed  for  methicillin  sensitive  S.  aureus  decreased  while  treatment  with
MSRA  antibiotics  increased.
Abbreviations: CA-MRSA, Community Acquired MRSA; SSTI, skin and soft tissue infections; MRSA, methicillin resistant Staphylococ-
us aureus;  MSSA, methicillin sensitive Staphylococcus aureus;  NAMCS, National Ambulatory Medical Care Survey; NHAMCS, National
ospital Ambulatory Medical Care Survey.
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Introduction
Staphylococcus  aureus  is a  bacterium  commonly
found on  normal  skin  and  in  the  nasal  ﬂora  of
healthy individuals  in  the  community.  It  is  esti-
mated  that  at  least  30%  of  the  US  population  are
permanently  colonized  or  are  transient  carriers  of
S. aureus  [1—3]. Since  the  development  of  antibi-
otics, S.  aureus  has  quickly  become  resistant  to
many antibiotics  that  are  commonly  used  to  treat
staphylococcal  infections,  such  as  beta-lactams
and macrolides  [1,2,4,5]. Currently,  methicillin-
resistant S.  aureus  (MRSA)  infections  are  endemic
in many  healthcare  institutions.  Furthermore,  new
strains of  MRSA  are  developing  within  communities,
affecting people  without  recognized  risk  factors  for
hospital-acquired  MRSA  (HA-MRSA)  [6—10].
Background and signiﬁcance
Beginning  in  the  1990s,  community-acquired  MRSA
(CA-MRSA)  infections  emerged  in  persons  with-
out recognized  risk  factors  associated  with  MRSA,
such as  a  prior  history  of  healthcare  exposure,
hospitalization,  surgery,  permanent  intravenous
lines and  other  indwelling  devices,  or  hemodialysis
[3,10—13].  Compared  with  the  antibiotic-resistant
nature of  HA-MRSA,  CA-MRSA  is more  susceptible
to antibiotic  treatment,  and  uncomplicated  cases
can be  treated  successfully  in  an  ambulatory  care
setting  [11].  The  majority  of  infections  caused  by
CA-MRSA  are  skin  and  soft  tissue  infections  (SSTIs)
that typically  present  as  boils,  abscesses,  or  celluli-
tis [10,14—16].
Patients  present  to  primary  care  with  lesions
that are  pustular  and  may  have  central  necrosis  or
purulent drainage.  The  lesions  may  be  reddened
and demonstrate  tender  and  palpable  ﬂuctuance.
Healthcare providers  commonly  treat  patients  pre-
senting with  SSTIs  with  antibiotics  used  to  treat
methicillin-sensitive  S.  aureus  (MSSA)  [4,5]. How-
ever, these  antibiotics  are  not  therapeutic  for
CA-MRSA,  leading  to  treatment  failure,  increasing
a patient’s  exposure  to  more  antibiotics,  allowing
possible contact  with  drainage  from  lesions  to  more
people  in  the  community,  and  increasing  the  asso-
ciated healthcare  costs  with  repeated  visits  to  the
primary care  ofﬁce.
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ased  incidence  of  SSTI  within  the  community,  suggesting
ibuting  factor.  Health  care  providers  are  recognizing  the
SA,  and  are  treating  SSTI  with  appropriate  antibiotics.
d  on  behalf  of  King  Saud  Bin  Abdulaziz  University  for
The  purpose  of  this  study  was  to  determine
f there  is  a relationship  between  the  increased
revalence of  SSTIs  and  CA-MRSA  by  comparing
he occurrences  in  1997—2002  and  2003—2008  and
hanges  in  prescribing  patterns  for  antibiotics  for
atients presenting  with  SSTIs.  We  hypothesize  that
y identifying  an  increase  in  CA-MRSA  within  a  pop-
lation, practitioners  will  more  likely  screen  for  the
resence of  MRSA  and  treat  with  the  appropriate
ntibiotics.
eview of the literature
A-MRSA  is  described  as  a leading  cause  of  SSTIs
n the  United  States  [10,17].  Approximately  80%
f CA-MRSA  infections  are  SSTIs  [10]. In  addition,
A-MRSA infections  have  emerged  among  patient
roups  with  risk  factors  not  associated  with  health-
are, which  includes  patients  with  sports  exposure,
ncarceration,  intravenous  drug  use,  overcrowded
ousing, and  poor  hygiene  [11,16,18—20]. However,
he epidemiology  of  CA-MRSA  is  becoming  increas-
ngly complex,  and  in  primary  care,  patients  found
o be  working  in  a healthcare  setting  are  also  at
ncreased  risk  [21,22]. Nonetheless,  the  prevalence
f CA-MRSA  is  increasing,  and  notably,  patients
resenting with  SSTIs  are  being  treated  without
onsideration of  the  drug-resistant  nature  of  MRSA
23].
Often,  treatment  of  abscesses  with  incision  and
rainage  is  an  adequate  treatment  for  SSTIs  caused
y Staphylococcal  infections  [23—25]. Studies  sug-
est that  treatment  of  SSTIs  after  surgical  drainage
nd treatment  with  prescription  of  antibiotics  not
ffective against  MRSA  infections  have  high  success
ates [23,25].  However,  in  an  international  survey
onducted  by  the  New  England  Journal  of  Medicine,
he majority  of  the  respondents  indicated  that
ntibiotic  treatment  would  be  prescribed  following
ncision  and  drainage  [26].
Antibiotics  classes  commonly  prescribed  for
SSA infections  are  the  beta-lactams  and
ephalosporins. However,  they  have  no  thera-
eutic effect  on  MRSA.  If  there  is  clinical  suspicion
f CA-MRSA  in  SSTIs  and  the  patient  is  described
s high  risk,  it  is  important  to  culture  SSTIs
nd prescribe  antibiotics  based  on  culture  and
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shanges  in  prescriptive  practices  in  skin  and  soft  ti
ensitivities  of  the  sample  [3,17,27].  Antibiotic
lasses shown  to  have  therapeutic  effects  on  MRSA
re ﬂuoroquinolones,  tetracyclines,  clindamycin,
nd trimethoprim/sulfamethoxazole  [20,23,28].
In an  outpatient  setting,  trimetho-
rim/sulfamethoxazole,  ﬂuoroquinolones,
etracyclines,  and  clindamycin  have  demon-
trated therapeutic  effects  on  CA-MRSA  with
onotherapy [20,23,25,28]. Linezolid  is  also  a
easible treatment  option  for  CA-MRSA;  however,
t is  very  expensive  compared  with  other  drugs
ith similar  efﬁcacies  and  should  be  reserved
or the  more  resistant  strains  associated  with
A-MRSA  [14,18,27].  Rifampicin  is  not  prescribed
or monotherapy  but  is  prescribed  in  combination
ith other  antibiotics  for  active  infections  for  a
ynergistic  effect.
ethods
 secondary  analysis  of  a  publicly  available  dataset
as used  to  examine  occurrences  of  patients  pre-
enting with  SSTIs  and  the  antibiotics  prescribed  for
reatment.
ata source
ublic  use  data  from  the  National  Ambulatory  Med-
cal Care  Survey  (NAMCS)  and  the  National  Hospital
mbulatory Medical  Care  Survey  (NHAMCS)  were
sed for  this  analysis.  The  NAMCS  is  a probabil-
ty sample  survey  of  ofﬁce-based  physicians  in  the
nited States.  The  NHAMCS  is  an  annual  probability
ample survey  of  hospital  outpatient  departments
nd emergency  departments  in  the  US.  The  US  Cen-
us Bureau  is  responsible  for  ﬁeld  operations  and
ata collection.
uman subjects’ protection
efore  2003,  NAMCS  and  NHAMCS  were  exempt
rom Institutional  Review  Board  Review.  In  February
003,  NAMCS  and  NHAMCS  protocols  were  approved
y the  CDC’s  National  Center  for  Health  Statis-
ics Research  Ethics  Review  Board.  Waivers  were
ranted  for  the  requirements  to  obtain  informed
onsent of  patients  and  patient  authorization  for
elease of  patient  medical  record  data  by  health-
are providers.ample
ll  patients  presenting  for  ambulatory  medical  care
ere identiﬁed  from  1997  to  2002  and  2003  to  2008
0
i
v
f infections  425
rom  the  NAMCS  and  NHAMCS  public  data  based
pon International  Classiﬁcation  of  Disease,  Ninth
evision, Clinical  Modiﬁcation  (ICD-9-CM)  codes
hat are  representative  of  SSTIs  and  the  prescrib-
ng patterns  of  antibiotics,  which  were  compared
ith SSTI  prevalence.
ata collection procedures
atient  surveys  from  1997  to  2002  and  2003  to  2008
ere analyzed.  Each  data  record  contains  patient
emographic  data  and  information  about  the  visit,
ncluding cause  of  injury,  diagnosis,  ambulatory  sur-
ical procedures,  NAMCS  and  NHAMCS  outpatient
epartment, medications,  and  disposition.  Up  to  3
iagnoses are  coded  according  to  the  ICD-9-CM,  and
p to  8  medications  were  recorded  per  visit.
Drugs are  coded  in  terms  of  their  generic
omponents  and  therapeutic  classes  using  Lex-
con Plus.  The  Lexicon  Plus  is  a  compre-
ensive database  of  all  prescription  and  non-
rescription drugs  available  in  the  US  market
http://www.multum.com/Lexicon.htm).
nalysis
o  estimate  the  number  of  visits  in  all  ambulatory
ettings, NAMCS  and  NHAMCS  data  were  combined
o produce  national  estimates,  and  the  data  were
eparated  into  2  groups  of  5  years  each  (1997—2002
nd 2003—2008).  The  frequencies  were  calculated,
s were  the  percentages  of  visits  of  selected  ICD-9
odes, patient  characteristics,  and  antibiotic  drugs
ith 95%  CI  and  standard  error  using  the  estimates
f the  US  population  provided  by  the  US  Census
ureau and  with  SAS  statistical  analysis  software.
o further  determine  which  factors  were  indepen-
ently associated  with  SSTIs,  a logistic  regression
nalysis of  all  visits  was  performed.  The  depend-
nt variable  was  deﬁned  as  a diagnosis  of  one  of
he SSTIs.  The  model  contains  the  following  inde-
endent  variables:  age,  sex,  race,  ethnicity,  and
xpected  source  of  payment.
esults
ased  upon  comparison  of  Tables  1  and  2, dur-
ng 1997—2002,  a total  of  4.8  million  visits  were
ade to  US  ambulatory  care  providers  for  selected
kin and  soft  tissue  infections,  which  represents
.6% (95%  CI  0.59—0.68)  of  all  visits.  The  incidence
ncreased during  2003—2008:  a  total  of  7.3  million
isits were  made  to  US  ambulatory  care  providers
or SSTS,  representing  0.83%  (95%  CI  0.78—0.88)
426  C.  Meddles-Torres  et  al.
Table  1  Frequency  and  percentage  of  ambulatory  care  visits  for  selected  SSTI  1997—2002.
Diagnosis  ICD-9-CM  code  No.  visits/1000
persons
% Visits  Std  err  of  %  95%  CI  of  percentage
All  visits  478,210  NA  NA  NA
Selected  SSTI  3977  0.6345  0.0203  0.0593—0.6756
Carbuncle  and  furuncle  680  123  0.0251  0.0034  0.0181—0.0320
Cellulitis/abscess  681/682  3146  0.4719  0.0181  0.4353—0.5085
Skin/subcutaneous  infection 686  436  0.0735  0.0062  0.0610—0.0860
Folliculitis  704.8  272  0.0640  0.0042  0.0554—0.0726
Unspeciﬁed  local  infection
and  subcutaneous  tissue
686.9  352  0.0432—0.0667
Table  2  Frequency  and  percentage  of  ambulatory  care  visits  for  selected  SSTI  2003—2008.
Diagnosis  ICD-9-CM  code  No.  visits/1000
persons
% Visits  Std  err  of  %  95%  CI  of  percentage
All  visits 582,806  NA  NA  NA
Selected  SSTI 7345  0.8283  0.0258  0.7777—0.8790
Carbuncle  and  furuncle 680  213  0.0379  0.0057  0.0268—0.0491
Cellulitis/abscess  681/682  6239  0.6562  0.0229  0.06112—0.7012
Skin/subcutaneous  infection 686  516  0.0659  0.0065  0.0532—0.0785
Folliculitis  704.8  377  0.0684  0.0070  0.0547—0.0821
Unspeciﬁed  local  infection
and  subcutaneous  tissue
686.9  420  0.0534  0.0057  0.0422—0.0645
Table  3a  Frequency  and  percentage  distribution  of  ambulatory  care  visits  for  selected  skin  and  soft  tissue  infec-
tions  by  selected  patient  and  their  visit  characteristics  from  1997  to  2002.
Characteristics  No.  visits/1000  persons  %  Distribution  95%  CI  of  percentage
Patient  sex
Female  1892  50.1706  47.8595—52.4818
Male  2085  49.8294  47.5182—52.1405
Patient  age
Under  15  years  453  15.0232  13.1032—16.9433
15—24  years  525  9.7090  8.1442—11.2737
25—44  years  1341  29.3982  27.0483—31.7480
45—64  years  1054  26.0881  24.0824—28.0939
65—74  years  292  8.9170  7.2548—10.5792
75  years  and  over  312  10.8645  9.0839—12.6452
Patient  race
White  3045  84.5600  82.1030—87.0169
Black  797  11.8553  9.5511—14.1595
Other  135  3.5847  2.3527—4.8168
Patient  ethnic  (selected)
Hispanic  or  Latino  619  11.0596  9.0556—13.0636
Non-Hispanic  or  Latino  2673  69.1289  65.2427—73.0150
Patient  paytype  (selected)
Private  insurance  1612  53.5738  51.3031—55.8445
Medicare  625  17.2859  15.3741—19.1977
Medicaid  754  12.9390  10.6459—15.2322
Self-pay  521  7.8414  6.6409—9.0419
No  charge  76  0.9825  0.4442—1.5207
Changes  in  prescriptive  practices  in  skin  and  soft  tissue  infections  427
Table  3b  Odds  ratio  estimates  1997—2002.
Effect  Point  estimate  95%  Wald  conﬁdence
limits
Age  1.003  0.975  1.032
Sex  1.418  1.296  1.552
Race  0.962  0.862  1.074
Ethnic  1.052  0.983  1.127
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Table  4b  Odds  ratio  estimates  2003—2008.
Effect  Point  estimate  95%  Wald  conﬁdence
limits
Age  —  —
Sex  1.424  1.283  1.581
Race  1.108  1.005  1.222
Ethnic  1.009  0.992  1.026
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sPaytype 1.003 0.984 1.023
f  all  visits.  This  is  an  increase  of  84.7%  when
ompared to  1997—2002  period.  This  increase  was
redominately  inﬂuenced  by  diagnoses  of  celluli-
is/abscess  (ICD-code  681/682),  which  increased  by
8.3% from  1997—2002  to  2003—2008.
A comparison  of  Tables  3a  and  4a  shows  the  visit
requency  and  percentage  distributions  for  SSTIs
ccording  to  the  patient  characteristics  of  sex,
ge, ethnic,  race,  and  payment  type.  When  com-
aring these  two  tables,  the  distributions  of  the
haracteristics  for  both  periods  reveal  no  signiﬁ-
ant differences  in  patient  demographics.  In  the
wo periods,  the  factor  of  sex  had  no  impact  on
he number  and  percentage  distribution  of  visits.
s for  age,  the  frequency  of  visits  in  the  two
eriods was  higher  for  persons  aged  25—64  than
a
T
q
Table  4a  Frequency  and  percentage  distribution  of  ambul
tions  by  selected  patient  and  their  visit  characteristics  from
Characteristics  No.  visits/1000  persons  
Patient  sex
Female  3567  
Male  3778  
Patient  age
Under  15  years  945  
15—24  years  1199  
25—44  years  1449  
45—64  years  1889  
65—74  years  414  
75  years  and  over  449  
Patient  race
White  5273  
Black  1752  
Other  320  
Patient  ethnic  (selected)
Hispanic  or  Latino  920  
Non-Hispanic  or  Latino  5773  
Patient  paytype  (selected)
Private  insurance  2535  
Medicare  945  
Medicaid  1715  
Self-pay  1362  
No  charge  149  Paytype 1.052  1.023  1.081
or  persons  in  other  age  groups.  White  patients
ade a greater  proportion  of  visits  compared
ith patients  from  non-Hispanic  or  Latino  back-
rounds.  Private  insurance  was  the  most  frequently
ecorded expected  source  of  payment,  accounting
or approximately  half  of  the  visits.  Medicare  and
edicaid  were  the  secondary  main  payment  sources
nd accounted  for  approximately  30%  of  all  visits
see Tables  3b  and  4b).
Comparing  the  antibiotics  prescribed  in
ables  5  and  6,  the  prescription  of  penicillins
ecreased  by  21.2%,  and  cephalosporin  pre-
criptions decreased  by  24%.  Both  of  these
ntibiotics are  not  effective  against  MRSA.
etracycline prescriptions  increased  by  471%,
uinolones/derivatives  increased  by  94%,  and
atory  care  visits  for  selected  skin  and  soft  tissue  infec-
 2003  to  2008.
%  Distribution  95%  CI  of  percentage
49.9280  47.6646—52.1915
50.0720  47.8085—52.3354
16.9828  14.9663—18.9993
12.7207  11.0256—14.4157
25.8729  23.9326—27.8133
29.7233  27.4093—32.0373
6.4361  5.3118—7.5605
8.2641  6.9493—9.5790
79.4950  77.0926—81.8975
15.7377  13.6140—17.8615
4.7672  3.3285—6.2059
11.1993  8.4747—13.9239
78.4539  74.9204—81.9874
48.8826  46.4834—51.2818
15.4835  13.8097—17.1572
15.0395  13.3532—16.7257
11.9660  10.5252—13.4068
1.1020  0.7760—1.4280
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Table  5  Frequency  and  percentage  of  antibiotic  drugs  at  ambulatory  care  visits  for  selected  SSTI  1997—2002.
Antibiotic  classes  No.  prescriptions/1000  Percentage  95%  CI  for  percentage
All  visits  3977  NA  NA
MSSA  antibiotics
Penicillins  451  11.9442  10.2671—13.6213
Cephalosporins  1711  36.6708  34.3055—39.0361
MRSA  antibiotics
Tetracyclines 45  1.9362  1.0442—2.8282
Fluoroquinolones  (quinolones/derivatives) 190  7.2426  5.8183—8.6669
Trimethoprim/sulfamethoxazole 30  1.0463  0.4846—1.6080
Antimicrobial  agents,  unspeciﬁed  18  0.3797  0.3073—0.4521
Miscellaneous  antibacterial  agents  136  2.1117  1.6867—2.5367
Table  6  Frequency  and  percentage  of  antibiotic  drugs  at  ambulatory  care  visits  for  selected  SSTI  2003—2008.
Antibiotic  classes  No.  prescriptions/1000  Percentage  95%  CI  for  percentage
All  visits  7345  NA  NA
MSSA  antibiotics
Penicillins  372  4.9020  3.7508—6.0532
Cephalosporins  1379  17.8713  15.8686—19.8739
MRSA  antibiotics
Tetracyclines 257  4.2060  3.0056—5.4064
Fluoroquinolones
(quinalones/derivatives)
370  6.6936  5.4205—7.9667
Trimetho-
prim/sulfamethoxazole
1349  13.3544  11.4070—15.3018
Antimicrobial  agents,
unspeciﬁed/miscellaneous
antibacterial  agents
1522  16.1383  13.8402—18.4364
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tsulfonamides  and  trimethoprim  increased  by
4396%. Overall,  prescriptions  for  drugs  that  are
effective  for  MSSA  decreased,  while  MRSA-speciﬁc
antibiotic prescriptions  increased.
Discussion
There  was  a  signiﬁcant  increase  in  SSTIs  from
1997—2002 to  2003—2008.  It is  estimated  that  SSTIs
increased  over  the  period  of  5 years  by  84.7%.
Patients present  to  ambulatory  care  settings  with
infections  associated  with  CA-MRSA  primarily  in  the
form of  abscesses,  which  increased  by  98.3%  over  a
period of  5  years.  Healthcare  providers  responded
to the  increases  in  SSTIs  and  rates  of  MRSA  by
prescribing antibiotics  that  are  successful  against
these ‘‘superbugs.’’  A  signiﬁcant  increase  in  the
prescription  of  antibiotics  effective  against  MRSA
(e.g., trimethoprim/sulfamethoxazole)  occurred  in
the period  of  2003—2005.  Inversely,  there  was
a decrease  in  the  prescription  of  penicillins  and
p
b
d
tephalosporins,  which  were  once  the  ﬁrst-line
ntibiotics prescribed  for  SSTIs.
Demographics  of  age,  sex,  race,  ethnicity,  and
ay type  did  not  reveal  any  signiﬁcant  changes  for
atients presenting  with  SSTIs  between  the  two
ime periods  examined.  The  source  of  payment  or
ay type  does  not  reﬂect  on  a patient’s  income  or
ocial status.  However,  due  to  the  increasing  cost
f fee-for-service  treatment,  the  expense  may  dis-
ourage patients  without  medical  insurance  from
eeking medical  treatment.  However,  there  was  an
verall increase  in  infection  rates.  This  could  be
ue to  both  antibiotic  resistance  occurring  at  over-
helming  rates  and  the  ease  of spread  of  SSTIs
y close  personal  contact,  exposure  to  draining
esions, and  inaccurate  diagnosis  and  treatment.
Limitations  in  this  study  included  the  inability
o separate  ﬁrst-time  visits  from  repeat  visits.  A
erson returning  for  an  unresolved  SSTI  may  have
een counted  more  than  one  time,  and  the  analysis
oes not  account  for  patient  follow-up.  In  addi-
ion, patients  may  have  been  diagnosed  with  more
C ssue
t
a
m
s
t
m
p
C
m
n
w
m
p
m
c
p
d
t
I
p
r
u
a
a
t
p
a
p
i
c
w
i
t
b
C
T
R
[
[
[
[
[
[
[hanges  in  prescriptive  practices  in  skin  and  soft  ti
han  one  type  of  SSTI  (e.g.,  cellulitis  and  abscess)
nd therefore  may  have  been  identiﬁed  by  two  or
ore ICD-9  codes.  The  category  of  antibiotics  pre-
cribed  does  not  specify  the  diagnosis  for  which
he drug  was  prescribed,  and  an  assumption  was
ade that  each  antibiotic  was  recorded  for  the
atient presenting  for  an  SSTI  during  that  visit.  The
DC database  does  not  have  current  procedural  ter-
inology (CPT)  coding  for  incision  and  drainage,
eedle aspiration,  or  debridement  of  abscesses  and
ounds. These  interventions  are  ﬁrst-line  treat-
ents  for  infections  that  ﬂuctuate  or  that  have
us that  could  be  drained.  There  was  also  no  infor-
ation to  determine  if  the  patient’s  infection  was
ultured  and  tested  for  antibiotic  sensitivity.
Further  study  is needed  to  determine  what
ercentages of  patients  experienced  incision  and
rainage,  debridement,  and  needle  aspirations  and
he susceptibility  patterns  of  cultured  infections.
f possible,  it  would  be  beneﬁcial  to  track  the
atients’ courses  of  treatment  from  diagnosis  to
esolution  to  estimate  duration  of  treatment.  The
se of  other  antibiotics,  such  as  rifampicin  as
n adjunct  therapy  and  linezolid,  should  also  be
nalyzed to  determine  changes  in  prescription  pat-
erns. Examination  of  reinfection  rates  would  also
rove to  be  useful  to  determine  which  patients
re at  risk  for  reinfection  and  to  establish  which
atients may  beneﬁt  from  decolonization  of  MRSA.
Overall,  this  study  demonstrates  that  there
s an  increase  in  infection  rates,  and  health-
are providers  are  recognizing  patients  presenting
ith SSTIs.  Patients  are  treated  according  to  the
ncrease  in  CA-MRSA  by  being  prescribed  antibiotics
hat have  been  proven  to  be  successful  against  the
acteria.
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